DASATINIB
Manufacturer: Apotex Corp.
Score: 142.0
PHYRAGO (dasatinib) is a kinase inhibitor used for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as those with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. It is also used for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. The recommended starting dosage is 100 mg orally once daily for chronic phase CML and 140 mg orally once daily for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL. Dose adjustments may be necessary based on strong CYP3A4 inhibitors or inducers, and patients should be monitored for myelosuppression, bleeding-related events, fluid retention, and other adverse reactions.
Dasatinib can cause fetal harm when administered to a pregnant woman, and breastfeeding is not recommended during treatment
Dose adjustments may be necessary based on strong CYP3A4 inhibitors or inducers
100 mg orally once daily
Not applicable
140 mg orally once daily
Not applicable
ASCIMINIB
Novartis Pharmaceuticals Corporation
BRIGATINIB
Takeda Pharmaceuticals America, Inc.
CHLORAMBUCIL
Waylis Therapeutics LLC
CHLORAMBUCIL
Woodward Pharma Services LLC
BORTEXOMIB
NorthStar RxLLC
BORTEXOMIB
Dr.Reddy's Laboratories Inc
BORTEXOMIB
Dr.Reddy's Laboratories, Inc.
PONATINIB HYDROCHLORIDE
Takeda Pharmaceuticals America, Inc.